Background and Aims: Chronic pulmonary aspergillosis (CPA) is associated with mortality in patients with Mycobacterium avium complex lung disease (MAC-LD). An Aspergillus-positive respiratory specimen often reflects colonization, and thus the clinical significance of Aspergillus isolation in MAC-LD patients is not well understood. The objective of this study was to investigate the clinical characteristics and outcomes of MAC-LD patients in whom Aspergillus was isolated from respiratory specimens.
Methods: We performed a retrospective review of the medical records of 329 MAC-LD patients. We compared the characteristics and mortality rates between patients with Aspergillus isolation and those without. All Aspergillus species detected from respiratory specimens within the follow-up period were reviewed.
Results: Aspergillus was detected in 40 (12.2%) of the 329 patients.
There were no significant differences in the clinical characteristics and mortality rates between patients with and without Aspergillus isolation.
Among the 40 patients with Aspergillus isolation, 9 (22.5%) developed CPA. CPA was most often caused by A. fumigatus. In the 40 Aspergilluspositive patients, patients with A. fumigatus isolation had a significantly higher mortality rate than those without (P < 0.001). The multivariate Cox proportional hazard model showed older age (P = 0.050), presence of respiratory comorbidities (P = 0.008), hypoalbuminemia (P < 0.001), and isolation of A. fumigatus (P = 0.005) to be prognostic factors for mortality in MAC-LD patients.
Conclusion: There were no significant difference in the mortality rates between patients with Aspergillus isolation and those without. However, isolation of A. fumigatus may be associated with poor prognosis in MAC-LD patients. Juntendo University Urayasu Hospital, Japan Background and Aims: Nintedanib was reported to reduce the change in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in the INPULSIS trial. In contrast, combination therapy with prednisolone, azathioprine, and N-acetylcysteine was reported to increase the risk of early hospitalization and death in the PANTHER trial. Therefore, clinicians cannot use this combination immunosuppressant therapy for IPF. However, there has been no research regarding combination therapy with nintedanib and prednisolone for IPF. Our aim is to investigate the efficacy and toxicity of combination therapy with nintedanib and prednisolone for IPF.
Methods: Sixty-four IPF patients who received nintedanib between
October 2015 and April 2018 were enrolled in this study. The diagnosis of IPF was based on the ATS/ERS/JRS/ALAT IPF statement in 2011. They were classified into two groups: patients treated with both nintedanib and prednisolone (NP group, n = 21) and patients treated with nintedanib only (N group, n = 43). Efficacy and toxicity were retrospectively compared between the two groups.
Results: Mean FVC before nintedanib initiation was 2195 AE 729 mL among all patients. Moreover, the mean annual decline in FVC was −15 mL. There were no significant differences in annual change in FVC between the two groups. Weight loss and diarrhoea occurred in 12 (18.5%) and 19 patients (26.7%), among all patients who received nintedanib. The incidence of weight loss and diarrhoea in the N group was significantly higher than in the NP group. However, there were no significant differences in the incidences of other adverse events, including nausea and liver dysfunction between the two groups. Although the incidence of acute exacerbation in the NP group was significantly higher than in the N group, there was no significant difference in survival time between the two groups. 
